| 000 | 01752 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250511204642.0 | ||
| 264 | 0 | _c19920417 | |
| 008 | 199204s 0 0 eng d | ||
| 022 | _a0959-8049 | ||
| 024 | 7 |
_a10.1016/0277-5379(91)90561-q _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGuilhot, F | |
| 245 | 0 | 0 |
_aA multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukaemia: interferon alfa-2b and hydroxyurea with or without cytosine arabinoside , preliminary results. _h[electronic resource] |
| 260 |
_bEuropean journal of cancer (Oxford, England : 1990) _c1991 |
||
| 300 |
_aS26 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCytarabine _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxyurea _xadministration & dosage |
| 650 | 0 | 4 |
_aInterferon Type I _xadministration & dosage |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 700 | 1 | _aLamagnère, J P | |
| 700 | 1 | _aHarousseau, J L | |
| 700 | 1 | _aTilly, H | |
| 700 | 1 | _aCasassus, P | |
| 700 | 1 | _aIfrah, N | |
| 700 | 1 | _aRochant, H | |
| 700 | 1 | _aBauters, F | |
| 700 | 1 | _aDine, G | |
| 700 | 1 | _aTanzer, J | |
| 773 | 0 |
_tEuropean journal of cancer (Oxford, England : 1990) _gvol. 27 Suppl 4 _gp. S26 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0277-5379(91)90561-q _zAvailable from publisher's website |
| 999 |
_c1805694 _d1805694 |
||